The fate of 10-year clinically recurrence-free survivors after definitive radiotherapy for T1-3N0M0 prostate cancer

Radiation Oncology Investigations

Volumn 6, Issue 2, 1998, Pages 103-108

  Johnstone, Peter A S ^a,b   Powell, Curt R ^a   Riffenburgh, Robert ^a   Bethel, Kelly J ^a   Kane, Christopher J ^a  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Pelvic lymph node dissection; Prostate cancer; Prostate specific antigen; Radiotherapy; Surgical staging

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME;

DISEASE-FREE SURVIVAL; HUMANS; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0031949397     PISSN: 10657541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1520-6823(1998)6:2<103::aid-roi6>3.0.co;2-1     Document Type: Article

References (15)

1. Bagshaw MA, Cox RS, Hancock SL: Control of prostate cancer with radiotherapy: Long-term results. J Urol 152:1781-1785, 1994.
2. Lee RJ, Sause WT: Surgically staged patients with prostatic carcinoma treated with definitive radiotherapy: Fifteen year results. Urology 43:640-644, 1994.
3. Powell CR, Huisman TK, Riffenburgh R, Saunders EL, Bethel KJ, Johnstone PAS: Outcome for surgically staged localized prostate cancer treated with external beam radiation therapy. J Urol 157:1754-1759, 1997.
4. Hanks GE, Hanlon A, Schultheiss T, Corn B, Shipley WU, Lee WR: Early prostate cancer: The results of radiation treatment from the Patterns of Care and Radiation Therapy Oncology Group Studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation. J Urol 152:1775-1780, 1994.
5. Schellhammer PF, El-Mahdi AM, Wright GL, Kolm P, Ragle R: Prostate-specific antigen to determine progression-free survival for localized carcinoma of prostate. Urology 42:13-18, 1993.
6. Stamey TA, Ferrari MK, Schmid HP: The value of serial prostate specific antigen determination 5 years after radiotherapy: Steeply increasing values characterize 80% of patients. J Urol 150:1856-1859, 1993.
7. Zagars GK, Pollack A, Kavadi VS, von Eschenbach AC: Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 32:293-306, 1995.
8. Babaian RJ, Kojima M, Saitoh M, Ayala AG: Detection of residual prostate cancer after external radiotherapy: Role of prostate specific antigen and transrectal ultrasonography. Cancer 75:2153-2158, 1995.
9. Kuban DA, El-Mahdi AM, Schellhammer PF: Prostate-specific antigen for pretreatment prediction and post-treatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 32:307-316, 1995.
10. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guide-lines for PSA following radiation therapy. Int J Radiat Oncol Biol Physics 37(5):1035-1041, 1997.
11. D'Amico AV, Hanks GE: Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 72:2638-2643, 1993.
12. Byar DP, Mostofi F: Carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatectomies, examined by the step section technique. Cancer 30:5-13, 1972.
13. Gleason DF: Classification of prostatic carcinomas. Cancer Chemother Rep 50:125-128, 1966.
14. Zeitman AL, Coen JJ, Shipley WU, Willett CG, Efird JT: Radical radiation therapy in the management of prostatic adenocarcinoma: The initial prostate specific antigen value as a predictor of treatment outcome. J Urol 151:640-645, 1994.
15. Anderson JR, Cain KC, Gelber RD: Analysis of survival by tumor response. J Clin Oncol 1:710-719, 1983.